Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Cash from Investing Activities: 2009-2024

Historic Cash from Investing Activities for Ani Pharmaceuticals (ANIP) over the last 16 years, with Dec 2024 value amounting to -$404.7 million.

  • Ani Pharmaceuticals' Cash from Investing Activities rose 98.45% to -$6.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$43.6 million, marking a year-over-year increase of 89.07%. This contributed to the annual value of -$404.7 million for FY2024, which is 2086.37% down from last year.
  • Ani Pharmaceuticals' Cash from Investing Activities amounted to -$404.7 million in FY2024, which was down 2,086.37% from -$18.5 million recorded in FY2023.
  • In the past 5 years, Ani Pharmaceuticals' Cash from Investing Activities ranged from a high of -$15.7 million in FY2022 and a low of -$404.7 million during FY2024.
  • Its 3-year average for Cash from Investing Activities is -$146.3 million, with a median of -$18.5 million in 2023.
  • Per our database at Business Quant, Ani Pharmaceuticals' Cash from Investing Activities spiked by 85.08% in 2022 and then plummeted by 2,086.37% in 2024.
  • Ani Pharmaceuticals' Cash from Investing Activities (Yearly) stood at -$68.3 million in 2020, then tumbled by 54.39% to -$105.5 million in 2021, then soared by 85.08% to -$15.7 million in 2022, then dropped by 17.62% to -$18.5 million in 2023, then crashed by 2,086.37% to -$404.7 million in 2024.